CGNL1

Across TCGA pan-cancer cohorts, CGNL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CGNL1 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CGNL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CGNL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where CGNL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.914	0.781	.015	13	view →
LUAD	DFS	Median	III,IV	0.272	0.696	.008	10	view →
UCEC	OS	Median	III,IV	0.333	0.904	.031	4	view →
LSCC	DFS	Quartile	II,III,IV	0.567	0.943	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CGNL1–PDAC (OS)

Open the PDAC breakdown →